Nevro Corp. (NVRO)

NYSE: NVRO · IEX Real-Time Price · USD
47.40
1.26 (2.73%)
May 17, 2022 4:00 PM EDT - Market closed
Market Cap1.67B
Revenue (ttm)386.14M
Net Income (ttm)-136.12M
Shares Out35.26M
EPS (ttm)-3.77
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume693,195
Open47.40
Previous Close46.14
Day's Range45.94 - 48.33
52-Week Range41.74 - 182.45
Beta1.03
AnalystsHold
Price Target80.48 (+69.8%)
Earnings DateMay 4, 2022

About NVRO

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and ...

IndustryHealth Care Equipment & Supplies
IPO DateNov 6, 2014
CEOD.Keith Grossman
Employees945
Stock ExchangeNYSE
Ticker SymbolNVRO
Full Company Profile

Financial Performance

In 2021, Nevro's revenue was $386.91 million, an increase of 6.87% compared to the previous year's $362.05 million. Losses were -$131.36 million, 58.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for NVRO stock is "Hold." The 12-month stock price forecast is 80.48, which is an increase of 69.79% from the latest price.

Price Target
$80.48
(69.79% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Nevro (NVRO) Stock Falls 19% Despite Q1 Earnings Beat

Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.

1 week ago - Zacks Investment Research

Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates

Nevro (NVRO) delivered earnings and revenue surprises of 11.71% and 2.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidance and Reiterates Full-Year 20...

REDWOOD CITY, Calif. , May 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for...

1 week ago - PRNewsWire

Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

Nevro to Report First Quarter 2022 Financial Results

Company to Host Conference Call on Wednesday, May 4, 2022 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , April 6, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that i...

1 month ago - PRNewsWire

Here's Why You Should Retain Nevro (NVRO) Stock For Now

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

1 month ago - Zacks Investment Research

Nevro's (NVRO) PDN Therapy Gets Noridian's Medicare Coverage

Latest favorable coverage decision for Nevro's (NVRO) PDN Therapy by Noridian is expected to allow the former to serve a wider patient pool.

2 months ago - Zacks Investment Research

Nevro Announces Positive Medicare Coverage Update from Noridian for the Treatment of Painful Diabetic Neuropathy

REDWOOD CITY, Calif., March 7, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...

2 months ago - PRNewsWire

Nevro's (NVRO) Q4 Earnings in Line, Revenues Beat Estimates

Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.

2 months ago - Zacks Investment Research

Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates

Nevro (NVRO) delivered earnings and revenue surprises of 0% and 0.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance

REDWOOD CITY, Calif., Feb. 23, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results fo...

2 months ago - PRNewsWire

Nevro to Participate in Wells Fargo 2022 MedTech R&D Spotlight Call Series

REDWOOD CITY, Calif., Feb. 18, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...

2 months ago - PRNewsWire

Nevro Announces Publication of 12-Month Data from SENZA-NSRBP Randomized Controlled Trial in Journal of Neurosurgery:...

REDWOOD CITY, Calif., Feb. 11, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...

3 months ago - PRNewsWire

Nevro to Present at Citi's 2022 Virtual Healthcare Conference

REDWOOD CITY, Calif., Jan. 31, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...

3 months ago - PRNewsWire

Nevro Named to 2022 Bloomberg Gender-Equality Index

REDWOOD CITY, Calif., Jan. 26, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...

3 months ago - PRNewsWire

Nevro Responds to Competitor's Announcement of FDA Approval for Painful Diabetic Neuropathy

REDWOOD CITY, Calif., Jan. 25, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...

3 months ago - PRNewsWire

Nevro to Report Fourth Quarter and Full-Year 2021 Financial Results

REDWOOD CITY, Calif., Jan. 24, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...

3 months ago - PRNewsWire

Nevro's (NVRO) Senza Gets FDA Nod for Expanded Labeling for NSRBP

Nevro's (NVRO) receipt of the FDA's approval for expanded labeling of its Senza SCS System is expected to cater to underserved patients.

3 months ago - Zacks Investment Research

Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for T...

REDWOOD CITY, Calif., Jan. 19, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...

3 months ago - PRNewsWire

Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant an...

REDWOOD CITY, Calif., Jan. 18, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...

3 months ago - PRNewsWire

Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue

REDWOOD CITY, Calif., Jan. 10, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...

4 months ago - PRNewsWire

Nevro's (NVRO) 10 kHz Therapy for Treatment of PDN Gets Coverage

Nevro (NVRO) receives coverage for its high-frequency 10 kHz therapy for the treatment of PDN.

4 months ago - Zacks Investment Research

Nevro (NVRO) Surges 5.2%: Is This an Indication of Further Gains?

Nevro (NVRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4 months ago - Zacks Investment Research

Nevro Announces UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Treatment of Painful Diabetic Neu...

REDWOOD CITY, Calif., Jan. 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, ...

4 months ago - PRNewsWire

Nevro Announces Settlement of IP Litigation with Nalu Medical

REDWOOD CITY, Calif., Dec. 21, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today ...

4 months ago - PRNewsWire